this page is secure
Dendrimers in Cancer Therapeutics and Diagnosis
Dendrimers represent a class of monodispersed synthetic macromolecules with a well defined three-dimensional structure of nanometer dimension in which a series of layered branches regularly extend from a central core molecule. Due to their precise nanoscale sizes, well-defined branched
structures, and various surface modifications, dendrimers have been extensively investigated in a wide range of applications in the biomedical field, particularly in the therapeutics and diagnosis of cancer. This article gives an overview of the recent advances of dendrimers and dendrimer-based
hybrid nanoparticles for cancer therapeutics and diagnosis applications.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics
Keywords: Dendrimer; Hybrid; Nanomedicine; anticancer drug delivery; bioassemblies; cancer diagnosis; dendritic branches; gene regulation; linear polymers; nanometer
Document Type: Research Article
Publication date: October 1, 2012
- Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts. - Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert